IP Verse

Betapharm Arzneimittel patent opposition analysis

CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Latest oppositions filed by Betapharm Arzneimittel

Explore patent oppositions filed by Betapharm Arzneimittel against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Last updated on: Jul 31, 2025

Patent Number	Title	Applicant	Opposition Date
Get instant updates on new opposition filings by the company
EP4321157	New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)	NOVARTIS	Jul 23, 2025
EP3494972	Combinations Of Dolutegravir And Lamivudine For The Treaetment Of Hiv Infection	VIIV HEALTHCARE	Sep 11, 2024
EP3626270	New Use	NOVARTIS	Jul 2, 2024
EP3294283	Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure	NOVARTIS	Dec 7, 2023
EP2959894	S1P Receptor Modulators For Treating Multiple Sclerosis	NOVARTIS	Jul 12, 2023
EP3461503	Methods Of Administering Tetrahydrobiopterin, Associated Compositions, And Methods Of Measuring	BIOMARIN PHARMACEUTICAL	Oct 28, 2022
EP2545939	Methods Of Administering Tetrahydrobiopterin, Associated Compositions, And Methods Of Measuring	BIOMARIN PHARMACEUTICAL	Sep 15, 2021
EP2340828	Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep Inhibitor	NOVARTIS	Apr 15, 2021
EP2493466	Novel Antitumoral Use Of Cabazitaxel	AVENTIS PHARMA	Mar 31, 2021
EP3395338	Rapid Dissolution Formulation Of Cinacalcet Hcl	AMGEN	Dec 9, 2020

Top competitors of Betapharm Arzneimittel

List of top competitors of Betapharm Arzneimittel based on patent oppositions.

NOVARTIS

AMGEN

AVENTIS PHARMA